PURPOSE: PET/CT with 68Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic 68Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder. METHODS: Eighty consecutive PC patients referred to 68Ga -PSMA-11 PET/CT were included in this retrospective analysis (biochemical relapse: n = 64; primary staging: n = 8; evaluation of therapy response/restaging: n = 8). In addition to whole-body PET/CT acquisition 60 min post injection early dynamic imaging of the pelvis in the first 8 min after tracer injection was performed. SUVmax of pathologic lesions was calculated and time-activity curves were generated and compared to those of urinary bladder and areas of physiologic tracer uptake. RESULTS: A total of 55 lesions consistent with malignancy on 60 min whole body imaging exhibited also pathologic 68Ga-PSMA-11 uptake during early dynamic imaging (prostatic bed/prostate gland: n = 27; lymph nodes: n = 12; bone: n = 16). All pathologic lesions showed tracer uptake within the first 3 min, whereas urinary bladder activity was absent within the first 3 min of dynamic imaging in all patients. Suvmax was significantly higher in PC lesions in the first 6 min compared to urinary bladder accumulation (p < 0.001). In the subgroup of PC patients with biochemical relapse the detection rate of local recurrence could be increased from 20.3 to 29.7%. CONCLUSIONS: Early dynamic imaging in 68Ga-PSMA-11 PET/CT reliably enables the differentiation of pathologic tracer uptake in PC lesions from physiologic bladder accumulation. Performance of early dynamic imaging in addition to whole body imaging 60 min after tracer injection might improve the detection rate of local recurrence in PC patients with biochemical relapse referred for 68Ga-PSMA-11 PET/CT.
PURPOSE: PET/CT with 68Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic 68Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder. METHODS: Eighty consecutive PC patients referred to 68Ga -PSMA-11 PET/CT were included in this retrospective analysis (biochemical relapse: n = 64; primary staging: n = 8; evaluation of therapy response/restaging: n = 8). In addition to whole-body PET/CT acquisition 60 min post injection early dynamic imaging of the pelvis in the first 8 min after tracer injection was performed. SUVmax of pathologic lesions was calculated and time-activity curves were generated and compared to those of urinary bladder and areas of physiologic tracer uptake. RESULTS: A total of 55 lesions consistent with malignancy on 60 min whole body imaging exhibited also pathologic 68Ga-PSMA-11 uptake during early dynamic imaging (prostatic bed/prostate gland: n = 27; lymph nodes: n = 12; bone: n = 16). All pathologic lesions showed tracer uptake within the first 3 min, whereas urinary bladder activity was absent within the first 3 min of dynamic imaging in all patients. Suvmax was significantly higher in PC lesions in the first 6 min compared to urinary bladder accumulation (p < 0.001). In the subgroup of PC patients with biochemical relapse the detection rate of local recurrence could be increased from 20.3 to 29.7%. CONCLUSIONS: Early dynamic imaging in 68Ga-PSMA-11 PET/CT reliably enables the differentiation of pathologic tracer uptake in PC lesions from physiologic bladder accumulation. Performance of early dynamic imaging in addition to whole body imaging 60 min after tracer injection might improve the detection rate of local recurrence in PC patients with biochemical relapse referred for 68Ga-PSMA-11 PET/CT.
Entities:
Keywords:
68Ga-PSMA-11 PET/CT; Biochemical recurrence; Early dynamic imaging; Prostate cancer
Authors: Pieter J De Visschere; Gert O De Meerleer; Jurgen J Fütterer; Geert M Villeirs Journal: AJR Am J Roentgenol Date: 2010-06 Impact factor: 3.959
Authors: Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-15 Impact factor: 9.236
Authors: Giuseppe Simone; Giovanni Battista Di Pierro; Rocco Papalia; Rosa Sciuto; Sandra Rea; Mariaconsiglia Ferriero; Salvatore Guaglianone; Carlo Ludovico Maini; Michele Gallucci Journal: World J Urol Date: 2015-01-11 Impact factor: 4.226
Authors: Ali Afshar-Oromieh; Henrik Hetzheim; Wolfgang Kübler; Clemens Kratochwil; Frederik L Giesel; Thomas A Hope; Matthias Eder; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-03 Impact factor: 9.236
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Christos Sachpekidis; Leyun Pan; Boris A Hadaschik; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss Journal: Am J Nucl Med Mol Imaging Date: 2018-10-20
Authors: Benedikt Kranzbühler; Hannes Nagel; Anton S Becker; Julian Müller; Martin Huellner; Paul Stolzmann; Urs Muehlematter; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-14 Impact factor: 9.236
Authors: Christos Sachpekidis; A Afshar-Oromieh; K Kopka; D S Strauss; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-14 Impact factor: 9.236
Authors: Christian Uprimny; Alexander Stephan Kroiss; Josef Fritz; Clemens Decristoforo; Dorota Kendler; Elisabeth von Guggenberg; Bernhard Nilica; Johanna Maffey-Steffan; Gianpaolo di Santo; Jasmin Bektic; Wolfgang Horninger; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-06 Impact factor: 9.236
Authors: Christian Uprimny; Anna Svirydenka; Josef Fritz; Alexander Stephan Kroiss; Bernhard Nilica; Clemens Decristoforo; Roland Haubner; Elisabeth von Guggenberg; Sabine Buxbaum; Wolfgang Horninger; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-16 Impact factor: 9.236
Authors: Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Steffi Teichert; Johanna Zörgiebel; Hans-Jürgen Wester; Sophie M Schneefeld; Almut C A Walte; James T Thackeray; Tobias L Ross; Frank M Bengel Journal: Mol Imaging Biol Date: 2018-08 Impact factor: 3.488